GDRX Stock Analysis: Goodrx Holdings | NASDAQ
Health Information Services | NASDAQ, USA | Market Cap: 1.269m USD | 12M Return: -27.3% | US38246G1085 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.47M
EPS Trend: 55.2%
Qual. Beats: 0
Rev. Trend: 76.5%
Qual. Beats: 3
Warnings
Tailwinds
Seasonality 5.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
GoodRx Holdings, Inc. (NASDAQ: GDRX) is a U.S.-based healthcare technology company that operates a price comparison platform helping consumers find lower prices on prescription drugs. Founded in 2011 and headquartered in Santa Monica, California, the company went public in September 2020 and is classified within the GICS Health Care Technology sub-industry, with a small-cap market valuation of approximately $925 million.
Beyond its core prescription pricing platform, GoodRx generates revenue from subscription programs, pharmaceutical manufacturer solutions, and telehealth services offered through the GoodRx Care platform, and has expanded into pet healthcare products. The company works with pharmacy benefit managers (PBMs)-third-party administrators that negotiate drug pricing and process prescription claims on behalf of health plans-making it part of the broader drug pricing and pharmacy benefit value chain in the United States.
- GLP-1 weight loss drug demand boosts prescription transaction volume
- GoodRx Gold subscription expansion drives recurring revenue growth
- Amazon Pharmacy competition pressures prescription pricing market share
| Net Income: 16.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -3.89 > 1.0 |
| NWC/Revenue: 56.22% < 20% (prev 52.47%; Δ 3.75% < -1%) |
| CFO/TA 0.09 > 3% & CFO 201.6m > Net Income 16.2m |
| Net Debt (295.2m) to EBITDA (169.1m): 1.75 < 3 |
| Current Ratio: 1.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (348.1m) vs 12m ago -2.55% < -2% |
| Gross Margin: 88.05% > 18% (prev 91.21%; Δ -3.16% > 0.5%) |
| Asset Turnover: 42.89% > 50% (prev 60.66%; Δ -17.77% > 0%) |
| Interest Coverage Ratio: 1.97 > 6 (EBIT TTM 80.5m / Interest Expense TTM 40.8m) |
| A: 0.19 (Total Current Assets 1.60b - Total Current Liabilities 1.16b) / Total Assets 2.34b |
| B: -0.60 (Retained Earnings -1.40b / Total Assets 2.34b) |
| C: 0.04 (EBIT TTM 80.5m / Avg Total Assets 1.83b) |
| D: 0.38 (Book Value of Equity 647.6m / Total Liabilities 1.70b) |
| Altman-Z'' = -0.02 = B |
| DSRI: 3.0 (Receivables 1.26b/202.3m, Revenue 785.2m/799.9m) |
| GMI: 1.04 (GM 91.21% / 88.05%) |
| AQI: 0.55 (AQ_t 0.30 / AQ_t-1 0.55) |
| SGI: 0.98 (Revenue 785.2m / 799.9m) |
| TATA: -0.08 (NI 16.2m - CFO 201.6m) / TA 2.34b) |
| Beneish M = -1.64 (Cap -4..+1) = CCC |
As of August 18, 2026, the stock is trading at USD 3.72 with a total of 1,304,219 shares traded. Over the past week, the price has changed by +1.64%, over one month by +18.47%, over three months by +48.80% and over the past year by -27.34%.
Current recommended Stop Loss: 3.40 (which is 8.6% or 1.7 ATR below the current price).
Goodrx Holdings has received a consensus analysts rating of 3.88. Therefore, it is recommended to buy GDRX.
- StrongBuy: 7
- Buy: 1
- Hold: 7
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 3.9 | 3.8% |
P/E Trailing = 62.0
P/E Forward = 5.4407
P/S = 1.6162
P/B = 1.9307
Revenue TTM = 785.2m USD
EBIT TTM = 80.5m USD
EBITDA TTM = 169.1m USD
Long Term Debt = 481.6m USD (from longTermDebt, last quarter)
Short Term Debt = 10.4m USD (from shortTermDebt, last quarter)
Debt = 591.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 52.4m
Net Debt = 295.2m USD (calculated: Debt 591.3m - CCE 296.1m)
Enterprise Value = 1.56b USD (1.27b + Debt 591.3m - CCE 296.1m)
Interest Coverage Ratio = 1.97 (Ebit TTM 80.5m / Interest Expense TTM 40.8m)
EV/FCF = 10.73x (Enterprise Value 1.56b / FCF TTM 145.7m)
FCF Yield = 9.32% (FCF TTM 145.7m / Enterprise Value 1.56b)
FCF Margin = 18.56% (FCF TTM 145.7m / Revenue TTM 785.2m)
Net Margin = 2.07% (Net Income TTM 16.2m / Revenue TTM 785.2m)
Gross Margin = 88.05% ((Revenue TTM 785.2m - Cost of Revenue TTM 93.8m) / Revenue TTM)
Gross Margin QoQ = 89.52% (prev 78.38%)
Tobins Q-Ratio = 0.67 (Enterprise Value 1.56b / Total Assets 2.34b)
Interest Expense / Debt = 6.90% (Interest Expense 40.8m / Debt 591.3m)
Taxrate = 44.81% (6.93m / 15.5m)
NOPAT = 44.4m (EBIT 80.5m * (1 - 44.81%))
Current Ratio = 1.38 (Total Current Assets 1.60b / Total Current Liabilities 1.16b)
Debt / Equity = 0.91 (Debt 591.3m / totalStockholderEquity, last quarter 647.6m)
Debt / EBITDA = 1.75 (Net Debt 295.2m / EBITDA 169.1m)
Debt / FCF = 2.03 (Net Debt 295.2m / FCF TTM 145.7m)
Total Stockholder Equity = 621.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.89% (Net Income 16.2m / Total Assets 2.34b)
RoE = 2.61% (Net Income TTM 16.2m / Total Stockholder Equity 621.6m)
RoCE = 7.30% (EBIT 80.5m / Capital Employed (Equity 621.6m + L.T.Debt 481.6m))
RoIC = 3.84% (NOPAT 44.4m / Invested Capital 1.16b)
WACC = 8.10% (E(1.27b)/V(1.86b) * Re(10.10%) + D(591.3m)/V(1.86b) * Rd(6.90%) * (1-Tc(0.45)))
Discount Rate = 10.10% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -92.49 | Cagr: -4.94%
[DCF] Terminal Value 76.58% ; FCFF base≈140.8m ; Y1≈152.2m ; Y5≈187.0m
[DCF] Fair Price = 23.98 (EV 2.86b - Net Debt 295.2m = Equity 2.57b / Shares 107.2m; r=8.35% [WACC [floored]]; 5y FCF grow 9.29% → 2.50% )
EPS Correlation: 55.18 | EPS CAGR: 6.15% | SUE: 0.0 | # QB: 0
Revenue Correlation: 76.55 | Revenue CAGR: 2.30% | SUE: 2.09 | # QB: 3
EPS current Quarter (2026-09-30): EPS=0.08 | Chg30d=+1.63% | Revisions=-17% | Analysts=11
EPS current Year (2026-12-31): EPS=0.31 | Chg30d=+0.03% | Revisions=-50% | GrowthEPS=-11.8% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=0.36 | Chg30d=+0.03% | Revisions=-25% | GrowthEPS=+16.0% | GrowthRev=+4.9%
[Analyst] Revisions Ratio: -50% (up=1, down=6)